ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer

Yao, Zhihao; Zhang, Henghui; Zhang, Xuejun; Zhang, Zhiyong; Jie, Jirong; Xie, Kunfeng; Li, Fei*; Tan, Wanlong*南方医科大学
Frontiers in Genetics2022-9-6DOI: 10.3389/fgene.2022.923768
1被引7阅读
引用收藏
分享

摘要

The tumor microenvironment (TME) not only provides fertile soil for tumor growth and development but also widely involves immune evasion as well as the resistance towards therapeutic response. Accumulating interest has been attracted from the biological function of TME to its effects on patient outcomes and treatment efficacy. However, the relationship between the TME-related gene expression profiles and the prognosis of bladder cancer (BLCA) remains unclear. The TME-related genes expression data of BLCA were collected from The Cancer Genome Atlas (TCGA) database. NFM algorithm was used to identify the distinct molecular pattern based on the significantly different TME-related genes. LASSO regression and Cox regression analyses were conducted to identify TME-related gene markers related to the prognosis of BLCA and to establish a prognostic model. The predictive efficacy of the risk model was verified through integrated bioinformatics analyses. Herein, 10 TME-related genes (PFKFB4, P4HB, OR2B6, OCIAD2, OAS1, KCNJ15, AHNAK, RAC3, EMP1, and PRKY) were identified to construct the prognostic model. The established risk scores were able to predict outcomes at 1, 3, and 5 years with greater accuracy than previously known models. Moreover, the risk score was closely associated with immune cell infiltration and the immunoregulatory genes including T cell exhaustion markers. Notably, the predictive power of the model in immunotherapy sensitivity was verified when it was applied to patients with metastatic urothelial carcinoma (mUC) undergoing immunotherapy. In conclusion, TME risk score can function as an independent prognostic biomarker and a predictor for evaluating immunotherapy response in BLCA patients, which provides recommendations for improving patients' response to immunotherapy and promoting personalized tumor immunotherapy in the future.

学科与关键词

关键词
bladder cancertumor microenvironmentrisk modelprognosisimmunotherapy response
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Genetics
发表日期
2022-09-06
卷期
第 13 卷
页码
923768
DOI
10.3389/fgene.2022.923768
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China; [82073162]

作者

  • Y

    Yao, Zhihao (第一作者)

    southern med univ

  • Z

    Zhang, Henghui

    southern med univ

查看全部 8 位作者收起作者
  • Z

    Zhang, Xuejun

    southern med univ

  • Z

    Zhang, Zhiyong

    southern med univ

  • J

    Jie, Jirong

    southern med univ

  • X

    Xie, Kunfeng

    southern med univ

  • L

    Li, Fei (通讯)

    southern med univ

  • T

    Tan, Wanlong (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417